These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22638564)

  • 1. Erdheim-Chester disease presenting with an intramedullary spinal cord lesion.
    Tzoulis C; Gjerde IO; Søfteland E; Neckelmann G; Strøm E; Vintermyr OK; Sviland L; Biermann M
    J Neurol; 2012 Oct; 259(10):2240-2. PubMed ID: 22638564
    [No Abstract]   [Full Text] [Related]  

  • 2. Epidural spinal involvement of Erdheim-Chester disease causing myelopathy.
    Hwang BY; Liu A; Kern J; Goodwin CR; Wolinsky JP; Desai A
    J Clin Neurosci; 2015 Sep; 22(9):1532-6. PubMed ID: 26119978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erdheim-Chester disease with predominant mesenteric localization: lack of efficacy of interferon alpha.
    Perlat A; Decaux O; Sébillot M; Grosbois B; Desfourneaux V; Meadeb J
    Joint Bone Spine; 2009 May; 76(3):315-7. PubMed ID: 19119043
    [No Abstract]   [Full Text] [Related]  

  • 4. Interferon-alpha in cardiac Erdheim-Chester disease.
    Monti L; Haroche J; Sciarra A; Balzarini L; Fiamengo B; Amoura Z; Graziani G
    J Am Coll Cardiol; 2011 Dec; 58(25):2695. PubMed ID: 22152958
    [No Abstract]   [Full Text] [Related]  

  • 5. Erdheim-Chester disease: multisystem involvement and management with interferon-alpha.
    Suzuki HI; Hosoya N; Miyagawa K; Ota S; Nakashima H; Makita N; Kurokawa M
    Leuk Res; 2010 Jan; 34(1):e21-4. PubMed ID: 19679354
    [No Abstract]   [Full Text] [Related]  

  • 6. Longitudinally Extensive Spinal Cord Lesion in Erdheim-Chester Disease.
    Simpson HD; Aksamit AJ; Zalewski NL
    JAMA Neurol; 2020 Nov; 77(11):1446-1447. PubMed ID: 32716494
    [No Abstract]   [Full Text] [Related]  

  • 7. Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease.
    Cohen-Aubart F; Emile JF; Maksud P; Galanaud D; Idbaih A; Chauvet D; Amar Y; Benameur N; Amoura Z; Haroche J
    Neurology; 2014 Sep; 83(14):1294-6. PubMed ID: 25171932
    [No Abstract]   [Full Text] [Related]  

  • 8. [Erdheim-Chester disease: report of a case with retroperitoneal involvement treated with interferon alpha-2a].
    Gil Ortega M; López Lozano E; Girela Baena E; Navarro Martinez N
    Med Clin (Barc); 2013 Sep; 141(5):227-8. PubMed ID: 23452672
    [No Abstract]   [Full Text] [Related]  

  • 9. Langerhans cell histiocytosis and Erdheim-Chester disease overlap syndrome with bone marrow involvement and type 2 diabetes mellitus.
    Chen M; Ding C; Lu T; Niu N; Han B
    Ann Hematol; 2018 Jan; 97(1):189-192. PubMed ID: 28889238
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical presentation, imaging and response to interferon-alpha therapy in Erdheim-Chester disease: case-based review.
    Iaremenko O; Petelytska L; Dyadyk O; Negria N; Fedkov D
    Rheumatol Int; 2020 Sep; 40(9):1529-1536. PubMed ID: 32572610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Erdheim-Chester disease].
    Haroche J; Cohen-Aubart F; Arnaud L; Hervier B; Charlotte F; Drier A; Gorochov G; Grenier PA; Cluzel P; Maksud P; Emile JF; Amoura Z
    Rev Med Interne; 2014 Nov; 35(11):715-22. PubMed ID: 24878295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha.
    Braiteh F; Boxrud C; Esmaeli B; Kurzrock R
    Blood; 2005 Nov; 106(9):2992-4. PubMed ID: 16020507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paroxysmal exertion-induced dystonia secondary to Erdheim-Chester disease.
    Baldacci F; Lucetti C; Vergallo A; Borelli P; Tessa C; Viacava P; Bonuccelli U
    Clin Neurol Neurosurg; 2013 Jul; 115(7):1105-6. PubMed ID: 22980524
    [No Abstract]   [Full Text] [Related]  

  • 14. Erdheim-Chester disease.
    Haroche J; Arnaud L; Cohen-Aubart F; Hervier B; Charlotte F; Emile JF; Amoura Z
    Rheum Dis Clin North Am; 2013 May; 39(2):299-311. PubMed ID: 23597965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symmetric giant xanthogranulomas in Erdheim-Chester disease.
    Taguchi T; Sano S; Iwasaki Y; Terada Y
    Eur J Nucl Med Mol Imaging; 2009 Jul; 36(7):1198. PubMed ID: 19296104
    [No Abstract]   [Full Text] [Related]  

  • 16. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients.
    Arnaud L; Hervier B; Néel A; Hamidou MA; Kahn JE; Wechsler B; Pérez-Pastor G; Blomberg B; Fuzibet JG; Dubourguet F; Marinho A; Magnette C; Noel V; Pavic M; Casper J; Beucher AB; Costedoat-Chalumeau N; Aaron L; Salvatierra J; Graux C; Cacoub P; Delcey V; Dechant C; Bindi P; Herbaut C; Graziani G; Amoura Z; Haroche J
    Blood; 2011 Mar; 117(10):2778-82. PubMed ID: 21239701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and positron emission tomography responses to long-term high-dose interferon-α treatment among patients with Erdheim-Chester disease.
    Cao XX; Niu N; Sun J; Cai H; Wang FD; Wang YN; Duan MH; Zhou DB; Li J
    Orphanet J Rare Dis; 2019 Jan; 14(1):11. PubMed ID: 30630516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erdheim-Chester Disease.
    Shah MV; Go RS
    Mayo Clin Proc; 2015 Sep; 90(9):1310. PubMed ID: 26355408
    [No Abstract]   [Full Text] [Related]  

  • 19. Erdheim-Chester disease associated with intramedullary spinal cord lesion.
    Takeuchi T; Sato M; Sonomura T; Itakura T
    Br J Radiol; 2012 Mar; 85(1011):e62-4. PubMed ID: 22391503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease.
    Cohen-Aubart F; Maksud P; Saadoun D; Drier A; Charlotte F; Cluzel P; Amoura Z; Haroche J
    Blood; 2016 Mar; 127(11):1509-12. PubMed ID: 26847247
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.